ライフサイエンスコーパス: small cell

1 In murine models of small-cell and non-small cell lung cancers, including pa

2 nal and micropapillary urothelial carcinoma, small cell, and squamous cell carcinoma subtypes of inva

3 ort: A 57-year-old male, with a diagnosis of small-cell cancer of the right lung (microcellular anapl

4 4,036), squamous cell carcinoma (n = 1,998), small cell carcinoma (n = 1,524), undifferentiated carci

5 Similar to published studies of small cell carcinoma of the lung, collaborative efforts

6 isease treatments has been extrapolated from small cell carcinoma of the lung.

7 or understanding the origin and treatment of small cell carcinoma of the urinary bladder has become e

8 Small cell carcinoma of the urinary bladder is a rare an

9 The direction of investigation of small cell carcinoma of the urinary bladder using novel

10 by additional neural autoantibody markers of small-cell carcinoma, including collapsin response-media

11 ls induce invasion of either single cells or small cell clusters of N-type cells.

12 is an increasing function of the density at small cell densities.

13 Small cell impermeants and PEG-20k in LVR solutions incr

14 confirmed in 1,828 patients (1,563 with non-small cell LC and 265 with small cell LC).

15 s (1,563 with non-small cell LC and 265 with small cell LC).

16 nd radiomic features in CT images of 258 non-small cell lung adenocarcinomas.

17 alignant neoplasms, including metastatic non-small cell lung cancer (mNSCLC).

18 into small cell lung cancer (n = 57) and non-small cell lung cancer (n = 33).

19 the most common malignancy distributed into small cell lung cancer (n = 57) and non-small cell lung

20 S, respectively) in early-stage I and II non-small cell lung cancer (NSCLC) after resection.

21 ted with these workflows, we analyzed 32 non-small cell lung cancer (NSCLC) and 22 breast cancer pati

22 qCC) are the two predominant subtypes of non-small cell lung cancer (NSCLC) and are distinct in their

23 Dose-dependent synergy was observed in Non-Small Cell Lung Cancer (NSCLC) and Head and Neck Squamou

24 of the most frequently mutated genes in non-small cell lung cancer (NSCLC) and is commonly comutated

25 f Notch signaling is a common feature of non-small cell lung cancer (NSCLC) and is correlated with po

26 YEATS2 gene is highly amplified in human non-small cell lung cancer (NSCLC) and is required for cance

27 le inhibitor directed against HuR, using non-small cell lung cancer (NSCLC) as a model.

28 aspiration (EBUS-TBNA) in patients with non-small cell lung cancer (NSCLC) can facilitate the select

29 molecule inhibitor (HL001) that induces non-small cell lung cancer (NSCLC) cell cycle arrest and apo

30 er siRNA to cytoplasm of KRAS mutant H23 Non-Small Cell Lung Cancer (NSCLC) cells for oncogene knockd

31 ion and invasion in KRAS- or EGFR-mutant non-small cell lung cancer (NSCLC) cells.

32 f its protein (BRG1) occur frequently in non-small cell lung cancer (NSCLC) cells.

33 whether radiomics features measured from non-small cell lung cancer (NSCLC) change during therapy and

34 Non-small cell lung cancer (NSCLC) comprises 85-90% of lung

35 ion within the tumor microenvironment in non-small cell lung cancer (NSCLC) has not yet been adequate

36 Non-small cell lung cancer (NSCLC) is characterized by early

37 ISPR, shRNA, and expression screens in a non-small cell lung cancer (NSCLC) model.

38 udinal blood samples from advanced stage non-small cell lung cancer (NSCLC) patients (n = 29) receivi

39 onse are unpredictable in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with cri

40 sis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the

41 Non-small cell lung cancer (NSCLC) patients with tumors harb

42 time, to our knowledge, in stage III-IV non-small cell lung cancer (NSCLC) patients.

43 uring DCs with pooled sera from multiple non-small cell lung cancer (NSCLC) patients.

44 dict poor long-term survival in resected non-small cell lung cancer (NSCLC) patients.

45 39 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients.

46 c (18)F-FDG PET for tumor delineation in non-small cell lung cancer (NSCLC) radiation therapy plannin

47 s used on the plasma of 48 patients with non-small cell lung cancer (NSCLC) to detect EGFR mutations.

48 inical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-bas

49 ntification of patients with early stage non-small cell lung cancer (NSCLC) with high risk of recurre

50 efinitive management of locally advanced non-small cell lung cancer (NSCLC), but long-term prospectiv

51 the HDI-based anticancer therapeutics in non-small cell lung cancer (NSCLC), in the present study, we

52 ost common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer.

53 To improve treatment outcomes in non-small cell lung cancer (NSCLC), preclinical models that

54 of subtype-specific prognostic genes for non-small cell lung cancer (NSCLC), we had previously propos

55 genic role in mediating tumorigenesis in non-small cell lung cancer (NSCLC).

56 ivity on clinical outcomes in RT-treated non-small cell lung cancer (NSCLC).

57 enes has revolutionized the treatment of non-small cell lung cancer (NSCLC).

58 hemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC).

59 ated by RNA sequencing for patients with non-small cell lung cancer (NSCLC).

60 th bevacizumab in patients with advanced non-small cell lung cancer (NSCLC).

61 th one common strategy remain unclear in non-small cell lung cancer (NSCLC).

62 t indices and prognosis in patients with non-small cell lung cancer (NSCLC).

63 h chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC).

64 type compounds that were active against lung small cell lung cancer (NSCLC).

65 of the most common type of lung tumors, non-small cell lung cancer (NSCLC).

66 termed GAS5-AS1 as a tumor suppressor in non-small cell lung cancer (NSCLC).

67 metformin is an effective treatment for non-small cell lung cancer (NSCLC).

68 rks a drastic change in the treatment of non-small cell lung cancer (NSCLC).

69 -oncogenic alterations commonly found in non-small cell lung cancer (NSCLC).

70 ronment and blood serum of patients with non-small cell lung cancer (NSCLC).

71 d as a novel therapeutic target expressed in small cell lung cancer (SCLC) and high-grade neuroendocr

72 ng mouse models of lung cancer, we show that small cell lung cancer (SCLC) and lung adenocarcinoma (A

73 Using small cell lung cancer (SCLC) as a model, we demonstrate

74 Small cell lung cancer (SCLC) is a common, aggressive ma

75 Small cell lung cancer (SCLC) is a devastating disease d

76 Small cell lung cancer (SCLC) is a devastating neuroendo

77 Small cell lung cancer (SCLC) is a difficult to treat su

78 Small cell lung cancer (SCLC) is characterized by preval

79 ich was markedly upregulated in Lu-iPSCs and small cell lung cancer (SCLC) lines and clinical specime

80 ic cell lines and xenografts of melanoma and small cell lung cancer (SCLC) origin.

81 genetically engineered mouse model of human small cell lung cancer (SCLC) to investigate the mechani

82 Small cell lung cancer (SCLC), as a proportion, makes up

83 plification are frequent oncogenic events in small cell lung cancer (SCLC).

84 st signal was detected in a patient with non-small cell lung cancer (SUVmax, 10.9; T/B ratio, 8.4) an

85 this study, we analysed LSD1 function in non-small cell lung cancer adenocarcinomas.

86 exhibits efficacy in pancreatic cancer, non-small cell lung cancer and breast cancer.

87 In small cell lung cancer and mesothelioma, the efficacy of

88 etables" pattern, and stronger for other non-small cell lung cancer and never smokers for the "Americ

89 ibitor resistance mechanisms.EGFR-mutant non-small cell lung cancer are often resistant to EGFR tyros

90 of forty-seven patients with early-stage non-small cell lung cancer before and after three weeks of t

91 targeting reduced mitogenic signaling in non-small cell lung cancer cell lines, suggesting that targe

92 receptor (EGFR) inhibitor, erlotinib, in Non-Small Cell Lung Cancer cell lines.

93 tro system to delineate their effects on non-small cell lung cancer cell proliferation and apoptosis.

94 nanosomes was assessed in H1299 and A549 non-small cell lung cancer cells, normal MRC9 lung fibroblas

95 73 patients with advanced non-small cell lung cancer from the prospective multicenter

96 as CTLA-4 and PD-1 can cure melanoma and non-small cell lung cancer in a subset of patients.

97 comes of patients diagnosed with stage 1 non-small cell lung cancer in the NLST to a nationally repre

98 t downregulation of LZTFL1 expression in non-small cell lung cancer is associated with recurrence and

99 y that resistance to targeted therapy in non-small cell lung cancer is highly dynamic, and also one w

100 Small cell lung cancer is initially highly responsive to

101 evolved resistance in an ALK rearranged non-small cell lung cancer line (H3122) to a panel of 4 ALK

102 limiting its utility in the treatment of non-small cell lung cancer metastases in the brain.

103 Non-small cell lung cancer patients carrying oncogenic EGFR

104 chemotherapy combined with radiation in Non-Small Cell Lung Cancer patients for use in clinical tria

105 Three hundred forty-eight non-small cell lung cancer patients underwent diagnostic (18

106 prompt a beneficial clinical response in non-small cell lung cancer patients who harbor activating mu

107 on a later CT scan in erlotinib-treated non-small cell lung cancer patients.

108 diomic features for somatic mutations in non-small cell lung cancer patients.

109 fter 7-10 d of erlotinib treatment in 50 non-small cell lung cancer patients.

110 tribution and dosimetry of (18)F-FAZA in non-small cell lung cancer patients.

111 cation of double-positive human NCI-H358 non-small cell lung cancer target tumors over single-positiv

112 The high genomic instability of non-small cell lung cancer tumors leads to the rapid develop

113 Eleven patients with inoperable non-small cell lung cancer underwent 2-5 thoracic PET/MRI sc

114 Small cell lung cancer was identified as an independent

115 cally proven or radiologically suspected non-small cell lung cancer were prospectively enrolled in th

116 cly available gene expression dataset of non-small cell lung cancer when combined with the existing p

117 In contrast, a non-small cell lung cancer xenograft expressing a constituti

118 a subcutaneous HER3 overexpressing H441 non-small cell lung cancer xenograft.

119 previously treated advanced KRAS-mutant non-small cell lung cancer, addition of selumetinib to docet

120 lected cancer patients, most especially with small cell lung cancer, although the long-term survival

121 urvival rates of small cell lung cancer, non-small cell lung cancer, and non-lung cancer patients all

122 In non-small cell lung cancer, anti-PD-1 antibodies have become

123 e (ProGRP), a highly sensitive biomarker for Small Cell Lung Cancer, as a model.

124 antiprogrammed cell death-1 therapy for non-small cell lung cancer, from May 2012 to September 2014.

125 ly identified as a prognostic marker for non-small cell lung cancer, in cerebrovascular pathogenesis

126 sustained since the 1-year survival rates of small cell lung cancer, non-small cell lung cancer, and

127 LST group undergoing surgery for stage 1 non-small cell lung cancer, those in the SEER-Medicare NLST

128 f this phenomenon occurs in ALK-positive non-small cell lung cancer, where targeted therapies are use

129 RAS are now routine in the management of non-small cell lung cancer.

130 ministering immunotherapy in early-stage non-small cell lung cancer.

131 ibitor used as second-line treatment for non-small cell lung cancer.

132 inhibitors remains a major challenge in non-small cell lung cancer.

133 and are associated with smoking-related non-small cell lung cancer.

134 owth factor receptor-targeted therapy in non-small cell lung cancer.

135 P) and Importin 8 (IPO8) to be stable in non-small cell lung cancer.

136 chemosensitive and chemoresistant models of small cell lung cancer.

137 ential as a new therapeutic approach for non-small cell lung cancer.

138 terogeneity and evolution in early-stage non-small cell lung cancer.

139 -FDG PET quantification in patients with non-small cell lung cancer.

140 dvanced melanoma, renal cell cancer, and non-small cell lung cancer.

141 ntial treatment strategy for KRAS mutant non-small cell lung cancers (NSCLC) and colorectal carcinoma

142 ective study, 36 patients with stage III non-small cell lung cancers (NSCLC), who underwent dynamic c

143 utation of LKB1, frequently occurring in non-small cell lung cancers (NSCLCs), is a predominant cauti

144 ial histologic sections from 90 archival non-small cell lung cancers from January 1, 2008, to Decembe

145 In murine models of small-cell and non-small cell lung cancers, including patient-derived xenog

146 e mutational "hotspots" in nonsmall cell and small cell lung cancers, supporting a possible role of o

147 e I/II clinical trial investigations for non-small cell lung cancers.

148 rative genomic and proteomic analysis of non-small cell lung carcinoma (NSCLC) cell lines revealed si

149 This method was applied to human non-small cell lung carcinoma (NSCLC) cell lines, embedded a

150 death worldwide, and among this cancer, non-small cell lung carcinoma (NSCLC) comprises the majority

151 midine ((18)F-FLT) PET in advanced-stage non-small cell lung carcinoma (NSCLC) patients with an activ

152 -driving genes in patients with advanced non-small cell lung carcinoma (NSCLC), especially in those w

153 le ((18)F-FMISO) uptake in patients with non-small cell lung carcinoma (NSCLC).

154 by which EZH2 expression is regulated in non-small cell lung carcinoma cells by oncogenic KRAS.

155 ntly in clinical trials for the treatment of small cell lung carcinoma, was synthesized using this st

156 olymerase chain reaction analyses of 102 non-small cell lung tumors, 61 ovarian tumors, 70 liver tumo

157 lioblastoma multiforme, prostate tumors, non-small cell lung tumors, and ovarian tumors, but not nont

158 ic (IRR, 2.07; 95% CI, 1.95 to 2.20) and non-small-cell lung (IRR, 1.69; 95% CI, 1.54 to 1.86) cancer

159 e CTCs from metastatic breast, colon and non-small-cell lung (NSCLC) cancer patients.

160 metastatic or polymetastatic extensive stage small-cell lung cancer (ES-SCLC) to the overall survival

161 based detection of early- and late-stage non-small-cell lung cancer (n = 518 late-stage validation co

162 ic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases.

163 abolism, thereby selectively sensitizing non-small-cell lung cancer (NSCLC) and glioblastoma (GBM) ce

164 mal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) are associated with poor

165 patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxe

166 of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured.

167 r ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine

168 who previously received radiotherapy for non-small-cell lung cancer (NSCLC) before receiving pembroli

169 that CLCb is specifically upregulated in non-small-cell lung cancer (NSCLC) cells and is associated w

170 Ras-independent, but not K-Ras-dependent non-small-cell lung cancer (NSCLC) cells.

171 Non-small-cell lung cancer (NSCLC) demonstrates remarkable m

172 Purpose Multiple agents for advanced non-small-cell lung cancer (NSCLC) have been approved in the

173 Non-small-cell lung cancer (NSCLC) is globally prevalent and

174 immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%.

175 plastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.

176 -associated cardiac injury for stage III non-small-cell lung cancer (NSCLC) is unclear, but higher he

177 r first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at site

178 ession profiling of individual CTCs from non-small-cell lung cancer (NSCLC) patients with remarkable

179 Is) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients.

180 ving anti-PD-1 or anti-PD-L1 therapy for non-small-cell lung cancer (NSCLC) presented hair repigmenta

181 ed survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with c

182 nt chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest surviva

183 inhibitors has changed the landscape of non-small-cell lung cancer (NSCLC) therapy, with 2 approvals

184 n both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) to try to improve inciden

185 its clinical-pathologic significance in non-small-cell lung cancer (NSCLC) was investigated.

186 patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programmed cell de

187 Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heter

188 reasingly used to treat locally advanced non-small-cell lung cancer (NSCLC), IMRT and three-dimension

189 ocally advanced or incompletely resected non-small-cell lung cancer (NSCLC), it remains uncertain whe

190 shown promise in patients with advanced non-small-cell lung cancer (NSCLC), particularly with squamo

191 blockade, have improved the treatment of non-small-cell lung cancer (NSCLC), supporting the premise t

192 l component in the care of patients with non-small-cell lung cancer (NSCLC), yet cardiac injury after

193 t for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).

194 ts with advanced squamous or nonsquamous non-small-cell lung cancer (NSCLC).

195 ly treated BRAF(V600E)-mutant metastatic non-small-cell lung cancer (NSCLC).

196 local tumor control of locally advanced non-small-cell lung cancer (NSCLC).

197 with platinum resistance and survival in non-small-cell lung cancer (NSCLC).

198 metabolism and are frequently mutated in non-small-cell lung cancer (NSCLC).

199 malignant pleural mesothelioma (MPM) or non-small-cell lung cancer (NSCLC).

200 l among patients with previously treated non-small-cell lung cancer (NSCLC).

201 ogenic transcription and tumor growth in non-small-cell lung cancer (NSCLC).

202 eviously treated, advanced or metastatic non-small-cell lung cancer (NSCLC).

203 reviously treated patients with advanced non-small-cell lung cancer (NSCLC).

204 rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC).

205 1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC).

206 line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC).

207 able clinical responses in patients with non-small-cell lung cancer (NSCLC).

208 metastases in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).

209 nts with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC).

210 dictive roles of TP53, KRAS, and EGFR in non-small-cell lung cancer (NSCLC).

211 t imparts a robust anti-tumor effect for non-small-cell lung cancer (NSCLC).

212 patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC).

213 as been associated with worse outcome in non-small-cell lung cancer (NSCLC).

214 ptor that we have shown is important for non-small-cell lung cancer (NSCLC).

215 temic therapy for patients with stage IV non-small-cell lung cancer (NSCLC).

216 ranial irradiation has been proposed in both small-cell lung cancer (SCLC) and non-small-cell lung ca

217 Small-cell lung cancer (SCLC) is a highly aggressive sub

218 pite favorable responses to initial therapy, small-cell lung cancer (SCLC) relapse occurs within a ye

219 Purpose Treating small-cell lung cancer (SCLC) remains a therapeutic chal

220 Effective targeted therapies for small-cell lung cancer (SCLC), the most aggressive form

221 In most patients with small-cell lung cancer (SCLC)-a metastatic, aggressive d

222 side for treatment of extensive-disease (ED) small-cell lung cancer (SCLC).

223 platin and etoposide in extensive stage (ES) small-cell lung cancer (SCLC).

224 ients with FGFR1-amplified squamous cell non-small-cell lung cancer (sqNSCLC; arm 1) or other solid t

225 ars with ALK-rearranged stage IIIB or IV non-small-cell lung cancer (with at least one measurable les

226 ts were enrolled, including 74 patients with small-cell lung cancer and eight with large-cell neuroen

227 , including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma.

228 n 10-50% of tumour cells in a mouse model of small-cell lung cancer and in human tumours.

229 of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerg

230 We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutation w

231 recapitulated in mutant KRAS homozygous non-small-cell lung cancer cells and in vivo, in spontaneous

232 Non-neuroendocrine Notch-active small-cell lung cancer cells are slow growing, consisten

233 ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) s

234 ertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR

235 EGFR tyrosine kinase inhibitor-resistant non-small-cell lung cancer models.

236 ad histologically or cytologically confirmed small-cell lung cancer or large-cell neuroendocrine tumo

237 ical specimens obtained from EGFR-mutant non-small-cell lung cancer patients with acquired EGFR tyros

238 Non-small-cell lung cancer patients with activating epiderma

239 thod to quantify radiosensitivity in 134 non-small-cell lung cancer patients, by using K-Means cluste

240 carboplatin-paclitaxel in patients with non-small-cell lung cancer receiving thoracic radiation.

241 l according to the time interval between non-small-cell lung cancer resection and the initiation of p

242 cacious when started 7 to 18 weeks after non-small-cell lung cancer resection.

243 Patients who recover slowly from non-small-cell lung cancer surgery may still benefit from de

244 Thus, small-cell lung cancer tumours generate their own microe

245 tactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer was reviewed for developmental ri

246 t-related adverse events in 74 patients with small-cell lung cancer were thrombocytopenia (eight [11%

247 to treat multiple brain metastases from non-small-cell lung cancer when highly active targeted thera

248 in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed fol

249 -naive patients with completely resected non-small-cell lung cancer who received postoperative multia

250 atients with EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases now have th

251 were eligible for inclusion, 42 (39%) in non-small-cell lung cancer, 36 (33%) in breast cancer, 25 (2

252 Three of five patients with small-cell lung cancer, all of whom had platinum-refract

253 In small-cell lung cancer, an aggressive neuroendocrine lun

254 b is used in advanced melanoma, advanced non-small-cell lung cancer, and in head and neck cancer.

255 umor immunity in patients with melanoma, non-small-cell lung cancer, and renal cell cancer.

256 oradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and low

257 high-grade serous ovarian, oesophageal, and small-cell lung cancer, are driven by somatic structural

258 ntrolled trials of systemic therapies in non-small-cell lung cancer, breast cancer, colorectal cancer

259 apy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy sch

260 ly or histologically confirmed limited-stage small-cell lung cancer, Eastern Cooperative Oncology Gro

261 ed treatments for patients with advanced non-small-cell lung cancer, especially focusing on data from

262 l versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression o

263 atients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had meas

264 s particularly active in platinum-refractory small-cell lung cancer, which tends not to respond to to

265 on with chemotherapy in select patients with small-cell lung cancer.

266 iotherapy treatment regimen in limited-stage small-cell lung cancer.

267 th tumour suppressive and pro-tumorigenic in small-cell lung cancer.

268 expressed in more than 80% of patients with small-cell lung cancer.

269 axel in previously treated patients with non-small-cell lung cancer.

270 ctivity, in patients with ALK-rearranged non-small-cell lung cancer.

271 ment; this report focuses on the cohort with small-cell lung cancer.

272 bination therapies) for stage IIIB or IV non-small-cell lung cancer.

273 ognostic marker for survival in resected non-small-cell lung cancer.

274 been referred for treatment of advanced non-small-cell lung cancer.

275 efit to a number of staging scenarios in non-small-cell lung cancer.

276 apy (SBRT) for patients with early-stage non-small-cell lung cancer.

277 A, we find that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated with

278 and it is often genetically activated in non-small-cell lung cancers (NSCLCs) by, for instance, mutat

279 We previously reported that human non-small-cell lung cancers (NSCLCs) oxidize glucose in the

280 adjuvant therapy guideline for resected non-small-cell lung cancers.

281 RET rearrangements are found in 1-2% of non-small-cell lung cancers.

282 vestigating adjuvant therapy in resected non-small-cell lung cancers.

283 Non-small-cell lung carcinoma (NSCLC) accounts for 85% of ma

284 Our current study using non-small-cell lung carcinoma (NSCLC) cell lines, animal mod

285 s the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal g

286 er 2013, solid tumour samples (including non-small-cell lung carcinoma [NSCLC], colorectal carcinoma,

287 Cancer (majority small-cell lung carcinoma [SCLC]) was detected in 66 of

288 Finally, we found that non-small-cell lung carcinoma that presented a cytonuclear Z

289 for treating aggressive cancers, such as non-small-cell lung tumors and metastatic melanoma.

290 nosed with cancer (prostate, colorectal, non-small-cell lung, non-Hodgkin lymphoma, breast, uterine,

291 gnosed with advanced breast, colorectal, non-small-cell lung, or pancreatic cancer from 2009 to 2012

292 P chimeras, we observed fluorescence also in small cells neighboring the motor neurons, identified as

293 btype in which the majority of tumors lacked small cell or neuroendocrine histology.

294 , excluding those with pancreatic tumours or small-cell or large-cell lung cancer, as well as those w

295 viously reported a general method to improve small, cell-permeable fluorophores which resulted in the

296 Exosomes are small, cell-released vesicles (40-100 nm in size) with t

297 carcinoma (OR = 1.45; P = 1.2 x 10(-3)) and small cell (SC) carcinoma (OR = 1.81; P = 0.01).

298 ifferentiated embryonal and undifferentiated small cells (SCU) progressively lose EGFR and ASAP1 expr

299 R maintained typical immaturity traits (e.g. small cell size, high amino acid contents and reduced su

300 samples, we found one squamous cell and two small-cell transformations.